Diagnostic Study; Contrast enhanced Magnetic Resonance Imaging of the lungs in children with CF.

Recruiting

• Conditions: 1. Cystic Fibrosis in children; <br />2. Gd-MRI; <br />3. Lung hypoperfusion.

• Registration Number: NL-OMON21165
• Lead Sponsor: Investigator initiated trial

Brief Summary

1. Armstrong, D., S. Hook, R. Carzino, G. Nixon, and K. Grimwood. 2000. Lower airway inflammation in cystic fibrosis infants. Pediatr Pulmonol:S5.3.<br> 2. Nixon, G. M., D. S. Armstrong, R. Carzino, J. B. Carlin, A. Olinsky, C. F. Robertson, and K. Grimwood. 2002. Early airway infection, inflammation, and lung function in cystic fibrosis. Arch Dis Child 87(4):306-11.<br> 3. Muhlebach, M. S., P. W. Stewart, M. W. Leigh, and T. L. Noah. 1999. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160(1):186-91.<br> 4. Rosenfeld, M., R. L. Gibson, S. McNamara, J. Emerson, J. L. Burns, R. Castile, P. Hiatt, K. McCoy, C. B. Wilson, A. Inglis, A. Smith, T. R. Martin, and B. W. Ramsey. 2001. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32(5):356-66.<br> 5. Tiddens, H. A. W. M. 2006. Chest Computed Tomography Scans should be considered as a routine investigation in Cystic Fibrosis. Pediatric Respiratory Reviews 7:202-208.<br> 6. Young, K., F. Aspestrand, and A. Kolbenstvedt. 1991. high resolution CT and bronchography in the asssessment of bronchiectasis. Acta Radiologica 32:439-441.<br> 7. Hansell, D. M. 1998. Bronchiectasis. Radiologic Clinics of North America 36:107-128.<br> 8. Munro, N. C., J. C. Cooke, D. C. Currie, B. Strickland, and P. J. Cole. 1990. Comparison of thin section computed tomography with bronchography for identifying bronchiectatic segments in patients with chronic sputum production. Thorax 45(2):135-9.<br> 9. de Jong, P. A., Y. Nakano, M. H. Lequin, R. Woods, P. D. Pare, and H. A. W. M. Tiddens. 2004. Progressive damage on high-resolution computed tomography despite stable lung function in CF. Eur Respir J 23:93-97.<br> 10. de Jong, P. A., A. Lindblad, L. Rubin, H. W.C., J. C. de Jongste, M. Brink, and H. A. Tiddens. 2006. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax 61:80-85.<br> 11. Tiddens, H. A. W. M. 2002. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol Suppl 34:228-231.<br> 12. Martinez, T. M., C. J. Llapur, T. H. Williams, C. Coates, R. Gunderman, M. D. Cohen, M. S. Howenstine, O. Saba, H. O. Coxson, and R. S. Tepper. 2005. High Resolution Computed Tomography Imaging of Airway Disease in Infants with Cystic Fibrosis. Am J Respir Crit Care Med.<br> 13. Quan, J. M., H. A. W. M. Tiddens, J. Sy, S. G. mcKenzie, M. D. Montgomery, P. J. Robinson, M. E. B. Wohl, and M. W. Konstan. 2001. A two-year randomized, placebo controlled trial of dornase alfa in young cystic fibrosis patients with mild lung function abnormalities. Journal of Pediatrics 139:813-820.<br> 14. Robinson, T. E., M. L. Goris, H. J. Zhu, X. Chen, P. Bhise, F. Sheikh, and R. B. Moss. 2005. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest 128(4):2327-35.<br> 15. de Jong, P. A., J. R. Mayo, K. Golmohammadi, Y. Nakano, M. H. Lequin, H. A. Tiddens, J. Aldrich, H. O. Coxson, and D. D. Sin. 2005. Estimation of cancer mortality associated with repetitive computed tomography scanning (CT) scanning in cystic fibrosis. Am J Respir Crit Care Med 173:199-203.<br> 16. de Jong, P. A., Y. Nakano, M. H. Lequin, and H. A. Tiddens. 2005. Dose reduction for CT in children with cystic fibrosis: is it feasible to reduce the number of images per scan. Pediatr Radiol 36:50-53.<br> 17. Puderbach, M., M. Eichinger, J. Gahr, S. Ley, S. Tuengerthal, A. Schmahl, C. Fink, C. Plathow, M. Wiebel, F. M. Muller, and H. U. Kauczor. 2007. Proton MRI appearance of cystic fibrosis: Comparison to CT. Eur Radiol 17(3):716-24.<br> 18. Eichinger, M., M. Puderbach, C. Fink, J. Gahr, S. Ley, C. Plathow, S. Tuengerthal, I. Zuna, F. M. Muller, and H. U. Kauczor. 2006. Contrast-enhanced 3D MRI of lung perfusion in children with cystic fibrosis-initial results. Eur Radiol.<br> 19. Failo, R., P. A. Wielopolski, H. A. W. M. Tiddens, W. C. J. Hop, G. P. Krestin, R. Pozzi Mucelli, and M. H. Lequin. 2007. Lung morphology assessment using Magnetic Resonance Imaging (MRI): a robust ultra-short TR/TE 2D Steady State Free Precession (SSFP) sequence in cystic fibrosis (CF) routine follow up. Submitted.<br> 20. Molinari, F., C. Fink, F. Risse, S. Tuengerthal, L. Bonomo, and H. U. Kauczor. 2006. Assessment of differential pulmonary blood flow using perfusion magnetic resonance imaging: comparison with radionuclide perfusion scintigraphy. Invest Radiol 41(8):624-30.<br> 21. Vonk-Noordegraaf, A., S. A. van Wolferen, J. T. Marcus, A. Boonstra, P. E. Postmus, J. W. Peeters, and A. J. Peacock. 2005. Noninvasive assessment and monitoring of the pulmonary circulation. Eur Respir J 25(4):758-66.<br> 22. Bellin, M. F. 2006. MR contrast agents, the old and the new. Eur J Radiol 60(3):314-23.<br> 23. Niendorf, H. P., J. Haustein, I. Cornelius, A. Alhassan, and W. Clauss. 1991. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 22(2):222-8; discussion 229-32.<br> 24. Wang, T., G. Schultz, H. Hebestreit, A. Hebestreit, D. Hahn, and P. M. Jakob. 2003. Quantitative perfusion mapping of the human lung using 1H spin labeling. J Magn Reson Imaging 18(2):260-5.<br> 25. Shellock, F. G., and E. Kanal. 1999. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 10(3):477-84.<br> 26. Bellin, M. F., M. Vasile, and S. Morel-Precetti. 2003. Currently used non-specific extracellular MR contrast media. Eur Radiol 13(12):2688-98.<br> 27. ACR guidance Document for Safe MR Practices:2007.ARJ:188,June 2007.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1. Age between 6-18 years old;

2. Diagnosis CF confirmed;

Exclusion Criteria

1. Inability to follow instructions of the investigator;

2. Current respiratory tract infection;

Study & Design

• Study Type: Interventional
• Study Design: Not specified